文献速递生殖医学

单细胞蛋白组学揭示Patl2缺陷卵母细胞胞质缺陷可经纺锤体移植挽救

Single-cell proteomics reveals cytoplasmic defects in Patl2-deficient oocytes rescued by spindle transfer.
PubMed 文献 · Hum Reprod · 2026-01-01

本研究利用Patl2敲除小鼠模型,通过单细胞蛋白组学发现Patl2-/-的MII卵母细胞存在蛋白含量异常,包括RNA结合蛋白和母源效应基因产物失调,导致受精后激活率和囊胚率下降。纺锤体移植可显著提高激活率和囊胚率至野生型水平,且对野生型卵母细胞无不良影响。

要点

  • Patl2-/-雌鼠体内MII率降低,但体外成熟率正常。
  • Patl2-/-卵母细胞经PIEZO-ICSI后激活率和囊胚率显著降低。
  • 纺锤体移植可挽救Patl2-/-卵母细胞的胚胎发育潜能。

核心结论

  • Patl2-/- MII卵母细胞存在胞质蛋白缺陷,纺锤体移植可有效挽救其发育能力。

研究设计与样本

  • 使用Patl2-/-小鼠(C57BL/6NTac-Patl2tm1a,外显子7缺失),2021年4月至2023年10月繁殖,从271只幼崽中获得36只纯合雌鼠。

主要发现

  • Patl2-/-雌鼠体内MII率(79.63%)低于Patl2+/+(89.39%,P=0.0123),但体外成熟率相似(48.74% vs 52.85%,P=0.5230)。
  • PIEZO-ICSI后,Patl2-/-卵母细胞的激活率(31.71% vs 76.74%,P<0.0001)和囊胚率(7.69% vs 42.42%,P=0.0237)显著降低。
  • Patl2-/-卵母细胞纺锤体正常率(78.57%)与野生型(86.00%)无显著差异(P=0.3491),钙振荡能力相似(A×F=6.15±4.80 vs 4.59±2.96,P=0.1453)。
  • 单细胞蛋白组学分析25个Patl2+/+和27个Patl2-/- MII卵母细胞,鉴定4882个蛋白,筛选3747个进行统计分析,发现1508个差异表达蛋白(q<0.05),其中992个下调,516个上调。
  • 纺锤体移植后孤雌激活,Patl2-/-卵母细胞的激活率(100%)和囊胚率(75%)显著高于单纯孤雌激活(激活率75.95%,P=0.0078;囊胚率45.00%,P=0.0128)。

临床怎么用

  • 纺锤体移植可能成为PATL2相关女性不孕(存在MII卵母细胞)的潜在治疗选择。
  • 对于Patl2-/-卵母细胞,辅助卵母细胞激活可能无效,因其钙响应正常。

局限性

  • Patl2-/-小鼠表型较PATL2变异患者轻,MII率高且无显著纺锤体异常,与先前报道矛盾。
  • 纺锤体移植在孤雌激活卵母细胞中进行,而非双亲胚胎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Can single-cell, mass spectrometry-based proteomics identify proteins associated with reduced developmental competence of Patl2-/- Metaphase II (MII) mouse oocytes and reveal therapeutic targets for Patl2-related infertility? SUMMARY ANSWER: Abnormal protein content is detected in Patl2-/- MII oocytes, which can be rescued by spindle transfer (ST). WHAT IS KNOWN ALREADY: PATL2 is an RNA-binding protein that represses maternal mRNA translation during oocyte maturation. PATL2 mutations in humans often cause germinal vesicle (GV) arrest, although some affected patients produce MII oocytes with reduced fertilization and embryo developmental potential. Consequently, oocyte donation is required. The Patl2-/- knockout mouse model offers a unique opportunity to study Patl2-related infertility and evaluate potential treatments. STUDY DESIGN, SIZE, DURATION: Patl2 -/- mice (C57BL/6NTac-Patl2tm1a), with deletion of exon 7, were bred from April 2021 to October 2023, yielding 36 homozygous females from 271 pups. To investigate the role of Patl2 at the MII stage, in vivo MII oocytes from Patl2-/- and Patl2+/+ females were collected for analysis of key quality markers and single-cell proteomics. Based on these results, maternal ST was tested to rescue abnormal embryo development. At least three replicates were conducted per experiment. PARTICIPANTS/MATERIALS, SETTINGS, METHODS: Four- to 12-week-old mice underwent superovulation and oocyte collection to assess in vitro and in vivo maturation. In vivo-matured MII oocytes were used to evaluate activation (AR) and blastocyst rates (BR) after PIEZO-ICSI, spindle configuration, and calcium oscillatory patterns following SrCl2 exposure. Vitrified-warmed oocytes were used for single-cell proteomics using a timsTOF ultra mass spectrometer operated in diaPASEF mode. ST involved transferring the Patl2-/- spindle to Patl2+/+ enucleated cytoplasm, followed by parthenogenetic activation (PA) via SrCl2 exposure. MAIN RESULTS AND THE ROLE OF CHANCE: Patl2 -/- females exhibit lower in vivo MII rates (79.63%) than Patl2+/+ females (89.39%, P = 0.0123) but similar in vitro maturation rates (GV-MII = 48.74%) compared to Patl2+/+ females (52.85%, P = 0.5230). After PIEZO-ICSI with wild-type sperm, reduced AR (Patl2-/- = 31.71%, Patl2+/+ = 76.74%, P < 0.0001) and BR (Patl2-/- = 7.69%, Patl2+/+ = 42.42%, P = 0.0237) were observed in knockout oocytes. However, Patl2-/- oocytes exhibited normal spindle rates (78.57%) as seen in Patl2+/+ oocytes (86.00%, P = 0.3491), as well as a similar capacity to sustain long-lasting calcium oscillations (A×F = 6.15 ± 4.80) compared to Patl2+/+ oocytes (A×F = 4.59 ± 2.96, P = 0.1453). Single-cell proteomics identified 4882 proteins and confirmed the absence of Patl2 in knockout oocytes, from analyzing 25 Patl2+/+ and 27 Patl2-/- MII oocytes. After filtering, 3747 proteins were used for statistical analysis, revealing 1508 differentially expressed proteins (q-value < 0.05; 992 downregulated, 516 upregulated in Patl2-/- oocytes). The levels of multiple RNA-binding proteins, some of which are proposed Patl2 interactors (Cpeb1, Eif4e1b), were found to be significantly reduced in Patl2-/- oocytes. Additionally, the protein products of several maternal effect genes (MEGs) implicated in mRNA regulation (Zar1, Igf2bp2) and cell cycle division (Tcl1a, Cdk1, Mos) were downregulated, while MEGs participating in epigenetic modifications (Zfp57, Trim28) were upregulated in the knockout group. Consistent with these observations, ST-PA treatment significantly increased AR (100%) and BR (75%) in the Patl2-/- oocytes in comparison to PA alone (AR = 75.95%, P = 0.0078; BR = 45.00%, P = 0.0128), effectively rescuing development to wild-type levels. Lastly, ST-PA treatment did not alter embryonic development in Patl2+/+ oocytes and produced outcomes comparable to PA alone, supporting the technical safety and applicability of the technique. LARGE SCALE DATA: The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE massIVE partner repository with the dataset identifier MSV000100606. LIMITATIONS, REASONS FOR CAUTION: Patl2 -/- mice exhibit a less severe phenotype compared to patients carrying PATL2 variants. Patl2-/- female mice display a high MII rate without significant spindle abnormalities, which contrasts with a previously published report. Additionally, ST treatment was conducted using parthenogenetically activated oocytes, rather than biparental embryos. WIDER IMPLICATIONS OF THE FINDINGS: ST represents a promising treatment for PATL2-related female infertility in patients with MII oocytes, as it appears to restore cytoplasmic defects linked to abnormal RNA-binding proteins and MEGs identified by single-cell proteomics. In contrast, other proposed treatments for poor embryo development, such as assisted oocyte activation, is unlikely to be effective since Patl2-/- oocytes show a normal calcium response. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the Special Research Fund (BOF) (starting grant BOF.STG.2021.0042.01 awarded to B.H.) and the Research Foundation-Flanders (FWO) (fellowship 1177425 N awarded to E.A.). B.H. has been receiving unrestricted educational funding from Ferring Pharmaceuticals (Aalst, Belgium). A.C.B., E.A., A.C., M.F-I-A., J.G., A.R., M.B., A.B., C.A., K.C.P., D.S., K.G., and F.V.M. have nothing to disclose. B.H. reports being board member of the Belgian Ethical Committee on embryo research.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Cardona Barberán A, Araftpoor E, Christodoulaki A, et al. Single-cell proteomics reveals cytoplasmic defects in Patl2-deficient oocytes rescued by spindle transfer. Hum Reprod. 2026. PMID: 42062216. doi:10.1093/humrep/deag073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。